תזונה ופעילות גופנית מצילים חולות סרטן שד

אתה אל תיקח ויטמינים ונוגדי חימצון. תפסיק ללחוץ בצורה אובסיסית על אחרים להפסיק לקחת משהו שעוזר להם. זה לא יעזור לך. בפורום הזה כולם על תוספים, כולם משקיעים הון בחברות הויטמינים. אח כמה שזה כואב לך הא? כמו שראית מנהל הפורום סותר אותך בכל פעם מחדש ואתה ממשיך לייצג את חברות התרופות. אתה אל תיקח ויטמינים, אל תגיד לאחרים להפסיק משהו שעוזר להם.

Folate AND Cancer—Timing Is Everything Cornelia M. Ulrich, MS, PhD; John D. Potter, MD, PhD JAMA. 2007;297:2408-2409.

: JAMA. 2007 Jun 6;297(21):2351-9. : Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group. Department of Community AND Family Medicine, Dartmouth Medical School, Hanover, NH, USA. [email protected] CONTEXT: Laboratory AND epidemiological data suggest that folic acid may have an antineoplastic effect in the large intestine. OBJECTIVE: To assess the safety AND efficacy of folic acid supplementation for preventing colorectal adenomas. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled, 2-factor, phase 3, randomized clinical trial conducted at 9 clinical centers between July 6, 1994, AND October 1, 2004. Participants included 1021 men AND women with a recent history of colorectal adenomas AND no previous invasive large intestine carcinoma. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive 1 mg/d of folic acid (n = 516) OR placebo (n = 505), AND were separately randomized to receive aspirin (81 OR 325 mg/d) OR placebo. Follow-up consisted of 2 colonoscopic surveillance cycles (the first interval was at 3 years AND the second at 3 OR 5 years later). MAIN OUTCOME MEASURES: The primary outcome measure was occurrence of at least 1 colorectal adenoma. Secondary outcomes were the occurrence of advanced lesions (> OR =25% villous features, high-grade dysplasia, size > OR =1 cm, OR invasive cancer) AND adenoma multiplicity (0, 1-2, OR > OR =3 adenomas). RESULTS: During the first 3 years, 987 participants (96.7%) underwent colonoscopic follow-up, AND the incidence of at least 1 colorectal adenoma was 44.1% for folic acid (n = 221) AND 42.4% for placebo (n = 206) (unadjusted risk ratio [RR], 1.04; 95% confidence interval [CI], 0.90-1.20; P = .58). Incidence of at least 1 advanced lesion was 11.4% for folic acid (n = 57) AND 8.6% for placebo (n = 42) (unadjusted RR, 1.32; 95% CI, 0.90-1.92; P = .15). A total of 607 participants (59.5%) underwent a second follow-up, AND the incidence of at least 1 colorectal adenoma was 41.9% for folic acid (n = 127) AND 37.2% for placebo (n = 113) (unadjusted RR, 1.13; 95% CI, 0.93-1.37; P = .23); AND incidence of at least 1 advanced lesion was 11.6% for folic acid (n = 35) AND 6.9% for placebo (n = 21) (unadjusted RR, 1.67; 95% CI, 1.00-2.80; P = .05). Folic acid was associated with higher risks of having 3 OR more adenomas AND of noncolorectal cancers. There was no significant effect modification by sex, age, smoking, alcohol use, body mass index, baseline plasma folate, OR aspirin allocation. CONCLUSIONS: Folic acid at 1 mg/d does not reduce colorectal adenoma risk. Further research is needed to investigate the possibility that folic acid supplementation might increase the risk of colorectal neoplasia.

: JAMA. 2007 Jun 6;297(21):2351-9. : Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group. Department of Community AND Family Medicine, Dartmouth Medical School, Hanover, NH, USA. [email protected] CONTEXT: Laboratory AND epidemiological data suggest that folic acid may have an antineoplastic effect in the large intestine. OBJECTIVE: To assess the safety AND efficacy of folic acid supplementation for preventing colorectal adenomas. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled, 2-factor, phase 3, randomized clinical trial conducted at 9 clinical centers between July 6, 1994, AND October 1, 2004. Participants included 1021 men AND women with a recent history of colorectal adenomas AND no previous invasive large intestine carcinoma. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive 1 mg/d of folic acid (n = 516) OR placebo (n = 505), AND were separately randomized to receive aspirin (81 OR 325 mg/d) OR placebo. Follow-up consisted of 2 colonoscopic surveillance cycles (the first interval was at 3 years AND the second at 3 OR 5 years later). MAIN OUTCOME MEASURES: The primary outcome measure was occurrence of at least 1 colorectal adenoma. Secondary outcomes were the occurrence of advanced lesions (> OR =25% villous features, high-grade dysplasia, size > OR =1 cm, OR invasive cancer) AND adenoma multiplicity (0, 1-2, OR > OR =3 adenomas). RESULTS: During the first 3 years, 987 participants (96.7%) underwent colonoscopic follow-up, AND the incidence of at least 1 colorectal adenoma was 44.1% for folic acid (n = 221) AND 42.4% for placebo (n = 206) (unadjusted risk ratio [RR], 1.04; 95% confidence interval [CI], 0.90-1.20; P = .58). Incidence of at least 1 advanced lesion was 11.4% for folic acid (n = 57) AND 8.6% for placebo (n = 42) (unadjusted RR, 1.32; 95% CI, 0.90-1.92; P = .15). A total of 607 participants (59.5%) underwent a second follow-up, AND the incidence of at least 1 colorectal adenoma was 41.9% for folic acid (n = 127) AND 37.2% for placebo (n = 113) (unadjusted RR, 1.13; 95% CI, 0.93-1.37; P = .23); AND incidence of at least 1 advanced lesion was 11.6% for folic acid (n = 35) AND 6.9% for placebo (n = 21) (unadjusted RR, 1.67; 95% CI, 1.00-2.80; P = .05). Folic acid was associated with higher risks of having 3 OR more adenomas AND of noncolorectal cancers. There was no significant effect modification by sex, age, smoking, alcohol use, body mass index, baseline plasma folate, OR aspirin allocation. CONCLUSIONS: Folic acid at 1 mg/d does not reduce colorectal adenoma risk. Further research is needed to investigate the possibility that folic acid supplementation might increase the risk of colorectal neoplasia.